Session » (0673–0690) Vasculitis – ANCA-Associated Poster I: Treatment Outcomes
- 9:00AM-11:00AM
-
Abstract Number: 0677
Analysis of Clinical Outcomes in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treated with Mepolizumab over 2 Years for Remission Induction or Maintenance: A Single Center Experience in Japan
- 9:00AM-11:00AM
-
Abstract Number: 0687
Avacopan for the Treatment of ANCA-associated Vasculitis. Real World Experience in Spain
- 9:00AM-11:00AM
-
Abstract Number: 0682
Avacopan in ANCA-associated Vasculitis Received Intensified Induction Therapy with Cyclophosphamide Plus Rituximab – Retrospective Case Serial of 12 Patients
- 9:00AM-11:00AM
-
Abstract Number: 0678
Benralizumab in Eosinophilic Granulomatosis with Polyangiitis
- 9:00AM-11:00AM
-
Abstract Number: 0688
Efficacy and Safety Experience with Avacopan Beyond 52 Weeks in the Early Access Program (EAP)
- 9:00AM-11:00AM
-
Abstract Number: 0685
Efficacy and Safety of Avacopan in Patients with ANCA-Associated Vasculitis Receiving Rituximab in a Phase 3 Trial
- 9:00AM-11:00AM
-
Abstract Number: 0674
Efficacy and Safety of Mepolizumab During Maintenance Therapy in Patients with Eosinophilic Granulomatosis with Polyangiitis
- 9:00AM-11:00AM
-
Abstract Number: 0675
Investigating the Impact of anti-IL5 Therapy in the Management of Relapsing and Refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA); A Three Year Longitudinal Perspective and Beyond
- 9:00AM-11:00AM
-
Abstract Number: 0679
Long-term Safety of Rituximab (Mabthera) in Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA): Rituximab Surveillance Study in VASculitis (RIVAS)
- 9:00AM-11:00AM
-
Abstract Number: 0676
Mepolizumab Can Achieve Glucocorticoid Discontinuation in Eosinophilic Granulomatosis with Polyangiitis Patients Regardless of IgE Levels: A Retrospective Study at a Single Center
- 9:00AM-11:00AM
-
Abstract Number: 0681
Real-World Outcomes for Remission Induction in Working-Age Adults with Severe Anti-Neutrophil Cytoplasmic Antibody-associated Vasculitis
- 9:00AM-11:00AM
-
Abstract Number: 0683
Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
- 9:00AM-11:00AM
-
Abstract Number: 0684
Report on Twelve Patients with Diffuse Alveolar Hemorrhage in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
- 9:00AM-11:00AM
-
Abstract Number: 0673
Reporting of Race, Ethnicity, Sex, Gender, Socioeconomic Status and Representativeness of Race and Ethnicity in ANCA-associated Vasculitis Randomized Trials
- 9:00AM-11:00AM
-
Abstract Number: 0680
Risk Factors for Hypogammaglobulinemia and Association with Relapse and Severe Infections in ANCA-Associated Vasculitis: A Retrospective Single-Centre Cohort Study
- 9:00AM-11:00AM
-
Abstract Number: 0686
Safety and Efficacy of Avacopan in Patients 65 Years and Older with ANCA-Associated Vasculitis
- 9:00AM-11:00AM
-
Abstract Number: 0690
Treating Patients with ANCA-Associated Vasculitis and Very Severe Renal Injury with an Intensified B Cell Depletion Therapy: Comparison with a Control Cohort Receiving a Conventional Therapy
- 9:00AM-11:00AM
-
Abstract Number: 0689
Use of Avacopan in Patients with ANCA-associated Vasculitis and Estimated Glomerular Filtration Rate < 15 mL/min/1.73m2